This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Novartis Ag. Active years: 2013.
Company Filing History:
Years Active: 2013
Title: Innovations of John Lei in the Hedgehog Signaling Pathway
Introduction
John Lei is an accomplished inventor based in Cambridge, MA (US). He has made significant contributions to the field of biomedical research, particularly in the area of cancer treatment. His work focuses on the modulation of the hedgehog signaling pathway, which plays a crucial role in various pathologies.
Latest Patents
John Lei holds a patent for "Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway." This patent relates to compounds that are instrumental in the diagnosis and treatment of conditions associated with the Hedgehog pathway, including tumor formation, cancer, neoplasia, and non-malignant hyperproliferative disorders. The compounds described in his patent are specifically formulated to target these critical health issues.
Career Highlights
John Lei is currently employed at Novartis AG, a leading global healthcare company. His role involves extensive research and development aimed at discovering innovative solutions for complex medical challenges. His dedication to advancing medical science is evident in his focused research efforts.
Collaborations
Throughout his career, John has collaborated with notable colleagues, including Miao Dai and Feng He. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries in their field.
Conclusion
John Lei's innovative work in the modulation of the hedgehog signaling pathway exemplifies the impact of dedicated research on cancer treatment. His contributions continue to pave the way for advancements in medical science and patient care.